Nhau dzeIndasitiri

Ongororo yakaitwa munguva pfupi yapfuura inoratidza mhedzisiro inovimbisa yekurapa kweCD7-targeted chimeric antigen receptor (CAR) T cell therapy mukurapa varwere vane relapse or refractory T-cell acute lymphoblastic leukemia (T-ALL) uye T-cell lymphoblastic lymphoma (T-LBL).

Musangano wegore negore wechi66 weAmerican Society of Hematology (ASH) uchaitwa kubva musi wa7-10 Zvita, 2024, paSan Diego Convention Center, uchiratidza tsvakiridzo inoshamisa uye kufambira mberi mu hematology.

Pasinei nematambudziko ari kuenderera mberi mukukura kwemaindasitiri nekutengeserana, zvipingamupinyi zveCAR-T therapy zviri kugadziriswa nenzira itsva inovimbisa: Tumor-Infiltrating Lymphocyte (TIL) therapy. Kubudirira uku kunoratidza nguva itsva mukurwisa bundu rakasimba.

Kurapa gomarara nenzira itsva kunogona zvakare kurapa nekugadzirisa masoja emuviri kuti ape zororo kwenguva refu kana kutorapa zvimwe zvirwere zvinorwisa muviri.

Musangano wegore negore wechi65 weAmerican Society of Hematology (ASH) wakaitwa kubva musi wa9 kusvika 12 Zvita 2023, muSan Diego, USA. Sechiitiko chikuru uye chakakwana chedzidzo yepamusoro ye hematology pasi rose, chinokwezva zviuru zvenyanzvi nenyanzvi kubva kumativi ese...